[CAS NO. 9015-68-3] L-Asparaginase
PRODUCTS SPECIFICATIONS [9015-68-3]
DESCRIPTION [9015-68-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | Unspecified |
| SMILES | - |
4 Publications Citing Use of MCE
Summary
L-Asparaginase (L-ASNase) is a deamidating enzyme that catalyses the hydrolysis of L-asparagine and L-glutamine, and can be used for the research of acute lymphoblastic leukemia. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis [1] .
In Vitro
L-Asparaginase has a cytotoxic effect on AML blasts and LSC subpopulations
[1]
.
L-Asparaginase is effective on both CD34
+
CD38
+
and CD34
+
CD38
+
LSC fractions, MSC and monocytes/macrophages partially counteracted the effect
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00526305 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2000 | Phase 4 |
| NCT01225874 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1999 | Not Applicable |
| NCT01518517 | ERYtech Pharma |
Acute Lymphoblastic Leukemia, in Relapse
|
December 2009 | Phase 2|Phase 3 |
| NCT01953770 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Childhood Acute Lymphoblastic Leukemia
|
February 2008 | Not Applicable |
| NCT02894645 | National University Hospital, Singapore |
Acute Lymphoblastic Leukemia (ALL)
|
October 2008 | Phase 4 |
| NCT00098839 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent Childhood Acute Lymphoblastic Leukemia
|
February 2005 | Phase 1|Phase 2 |
| NCT01313078 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Ovarian Neoplasms|Fallopian Tube Neoplasms|Primary Peritoneal Neoplasms
|
January 2010 | Phase 2 |
| NCT03286634 | National Hospital Organization Nagoya Medical Center |
Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer
|
April 18, 2017 | Phase 2 |
| NCT00873093 | National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
March 2009 | Phase 2 |
| NCT00187057 | St. Jude Children´s Research Hospital|Children´s Hospital of Philadelphia|National Cancer Institute (NCI) |
Ataxia-Telangiectasia
|
September 2002 | Not Applicable |
| NCT04440267 | wang, jianxiang|Institute of Hematology & Blood Diseases Hospital |
Acute Leukemia of Ambiguous Lineage
|
June 20, 2020 | Phase 2 |
| NCT02197650 | ERYtech Pharma |
Acute Lymphoblastic Leukemia
|
||
| NCT03071822 | The University of Hong Kong |
Peripheral T Cell Lymphoma
|
February 24, 2017 | Phase 4 |
| NCT00526175 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2001 | Phase 4 |
| NCT02544425 | Samsung Medical Center |
Extranodal NK-T-Cell Lymphoma
|
February 21, 2016 | Phase 2 |
| NCT00187122 | St. Jude Children´s Research Hospital |
Lymphoblastic Lymphoma
|
March 1993 | Not Applicable |
| NCT03623087 | The University of Hong Kong |
Non-Hodgkin´s Lymphoma, Relapsed|Non-Hodgkin T-cell Lymphoma|Natural Killer+T-Cell Lymphoma, Nasal and Nasal-Type
|
July 1, 2017 | Phase 3 |
| NCT03150693 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia
|
June 1, 2017 | Phase 3 |
| NCT04230330 | National Cancer Centre, Singapore|Bristol-Myers Squibb |
NK+T Cell Lymphoma
|
December 12, 2019 | Phase 1 |
| NCT00590915 | Phoenix Children´s Hospital|Fisher Bioservices|Jazz Pharmaceuticals |
Leukemia, Acute Lymphoblastic|Acute Lymphoid Leukemia
|
||
| NCT01910428 | ERYtech Pharma |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
October 2013 | Phase 1 |
| NCT00526409 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2005 | Phase 4 |
| NCT00136435 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Queen Elizabeth II Health Sciences Centre |
Acute Lymphoblastic Leukemia
|
June 2002 | Phase 2 |
| NCT02036489 | PETHEMA Foundation |
Acute Lymphobkastic Leukemia
|
January 2008 | Phase 4 |
| NCT01358253 | Ruijin Hospital |
Acute Lymphoblastic Leukemia
|
December 2010 | Phase 4 |
| NCT03079544 | Rong Tao|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Extranodal NK-T-Cell Lymphoma, Nasal Type
|
March 8, 2017 | |
| NCT00131053 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 2 |
| NCT00176462 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Acute Lymphocytic Leukemia
|
February 2001 | Phase 2 |
| NCT00854425 | Fudan University |
Lymphoma
|
June 2008 | Phase 2 |
| NCT00131027 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 3 |
| NCT02419755 | St. Jude Children´s Research Hospital |
Mixed Lineage Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia
|
April 14, 2015 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture and light
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
0.1 M HCL : 50 mg/mL (ultrasonic and adjust pH to 3 with HCl)
H 2 O : 1 mg/mL (ultrasonic and warming and heat to 50°C)
-
1.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (Infinity mM); Clear solution; Need ultrasonic
Synonyms